Back to search

Norway· NO-ID_682F32FC-616B-4344-888B-9199A933F804

Ethinyl-Oestradiol effik

A ethinylestradiol product containing etinyløstradiol, registered in Norway by Laboratories Effik. The same ATC class is registered in 3 of our 19 countries.

ATC G03CA01

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedEthinyl-Oestradiol effikATCG03CA01REGISTER NO.NO-ID_682F32FC-616B-4…PACKS LISTED3CHECKEDSeptember 25, 2026

Where it is registered

Ethinylestradiol is registered in 3 of 19 countries.

Countries holding a registration under ATC G03CA01 (ethinylestradiol), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 2 of them publish a price we can compare per daily dose

Ethinylestradiol · ATC G03CA01

3 / 19 countries

  • Finlandprice
  • Netherlands
  • Norwayprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FEST (Norway)
Active substance
Etinyløstradiol
Manufacturer
Laboratories Effik
Country
Norway (NO)
ATC code
G03CA01
ATC class
Ethinylestradiol
Defined daily dose
25 mcg, O
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

  • no_merkevare_id
    ID_682F32FC-616B-4344-888B-9199A933F804
  • no_varenummer
    229741
    15
  • gtin
    3400935175311

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

463 interactions on record for ethinylestradiol.

Graded by severity as the source publishes them — 40 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ethinylestradiol · interactions on record

463 records

  • 40 severe
  • 372 moderate
  • 49 minor

Most severe, free to view

  • Tranexamic acidB02AA02severe
  • HeminB06AB01severe
  • BosentanC02KX01severe
  • GriseofulvinD01AA08severe

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ethinylestradiol in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ethinylestradiol products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • France · Ethinyloestradiol Effik
  • Netherlands · Acelyn

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8d32d6b5-bf12-4584-b57f-fd9b3e91abf7
GET /v1/drugs/8d32d6b5-bf12-4584-b57f-fd9b3e91abf7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablett",
  "source": "fest",
  "status": "A",
  "atc_name": "Etinyløstradiol",
  "merkevare_id": "ID_682F32FC-616B-4344-888B-9199A933F804",
  "name_form_strength": "Ethinyl-Oestradiol effik tab 50 mikrog",
  "prescription_group": "C"
}

See everything about ethinylestradiol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.